Global technology company ATMI has invested in sterile connectors and fill technology developed by US fluids transfer and packaging solutions provider Medical Instill Technologies.
With the help of INTACT Filler technology, multiple products can be sterile filled into a range of containers and dosing devices in conditions significantly less stringent and less expensive than clean rooms.
The investments focus on the Medinstill INTACT family of products, which will be deployed in sterile filling, multiple-dose dispensing, transfer and packaging sterilisation solutions.
The deployment of the new technologies will address existing critical issues in industries including pharmaceutical, biotech and healthcare.
Medinstill chairman Daniel Py said that ATMI has a global reach in biopharmaceutical manufacturing which enables the company to bring products with better safety levels to those in need.
"The INTACT technology provides a means to rapidly reduce drug shortages while overcoming the difficulties associated with installing and running aseptic lines in emerging markets, such as access to specially trained personnel, all at a fraction of the cost of traditional aseptic filling lines," Py added.
Both companies have formed a joint venture to market and manufacture the technology for the biopharmaceutical industry.
INTACT Connector technology, which will allow for sterile re-use of disposable connectors, has been licenced by ATMI for the biopharmaceutical industry.